Low Dose Naltrexone (LDN)
Low-dose naltrexone (LDN) usually refers to naltrexone taken at much lower doses than standard addiction-treatment dosing (commonly in the ~0.5–4.5 mg range, though practices vary). It’s most often discussed for immune/inflammation-related conditions, chronic pain, and fatigue, and some people explore it for mood/energy and general “system stabilization.” LDN is typically compounded (because low doses aren’t standard tablet strengths), and people may take it at night or morning depending on how it affects sleep.
-
This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.
-
Within PFS/PSSD/PAS communities, LDN is discussed in relation to its potential interactions with opioid receptor signaling and immune/inflammatory pathways. Naltrexone is an opioid receptor antagonist. In the "LDN" framework, the idea is that a short-lived blockade may lead to a rebound increase in endogenous opioid signaling (endorphins/enkephalins) and downstream effects on immune signaling and stress tolerance. LDN is also discussed for potential microglial / neuroinflammation modulation (often framed via Toll-like receptor pathways). These mechanisms may interact with pathways involving opioid signaling, immune/inflammatory regulation, or stress response that are often discussed in relation to PFS / PSSD / PAS.
-
Mixed Responses With Dose-Sensitive Destabilization Risk (for PFS/PSSD/PAS):
Among individuals with PFS, PSSD, or PAS, low-dose naltrexone (LDN) is generally discussed as a symptom-targeting tool rather than a corrective treatment for the underlying condition. Some users report modest benefits such as improved energy, slightly better mood or stress tolerance, and occasional libido changes, while many report no meaningful effect. A subset of reports describe worsening or destabilization, including sleep disruption, feeling “wired” or off, increased anxiety or irritability, or sexual side effects such as reduced libido or erectile issues, with occasional reports of more pronounced crashes.
Responses to LDN are often described as dose-sensitive, leading many within the community to emphasize very slow titration and to treat sleep or sexual worsening as signals to pause or reassess rather than push through. Although LDN is often viewed as lower risk than many psychoactive or hormonal agents, it is not considered universally benign. As a result, it is commonly approached as a clinician-supervised experiment, particularly in individuals who are already highly reactive.
Evidence basis: established pharmacology of naltrexone; LDN is supported mainly by broader off-label clinical use and mixed-condition studies, plus anecdotal reports for PFS/PSSD/PAS-specific outcomes (forums/self-reports). No controlled studies establishing LDN as a treatment for PFS/PSSD/PAS specifically.
-
Public comments reflect individual experiences and opinions. They are not medical advice and may not be accurate or representative.